FDA decision: DTX401 (pariglasgene brecaparvovec) by Ultragenyx Pharmaceutical (in 2026)

Coinbase·Jun 18

This story is reported by Coinbase. Read what other outlets are saying below, then open the original report for full details.

Full coverage

1

FDA fast-tracks gene therapy for rare storage disease, decision Aug. 23

Stock Titan·Feb 23

2

Ultragenyx Vaults Toward Commercialization as FDA Accepts Landmark Gene Therapy BLA

FinancialContent·Apr 2

3

Biopharma bites: Layoffs at Ultragenyx, Gilead's licensing deal, plus a pair of PIPEs and a 340B update

FirstWord Pharma·Feb 13

4

Bedford Biz Roundup – February 2026

The Bedford Citizen·Feb 26

5

StockWatch: Ultragenyx, Mereo Plummet on Brittle Bone Candidate Failures

Genetic Engineering and Biotechnology News·Jan 4

6

JPM26: 2025 a “breakout year” for rare disease biotechs

Clinical Trials Arena·Jan 14

7

What’s Next for AAV Gene Therapies in 2024?

Pharmaceutical Technology·Mar 11